Organon Reports Q4 Net Loss Driven by $301M Goodwill Impairment; Audit Review Initiated
Summary
Organon & Co. reported a Q4 net loss of $205 million, including a $301 million goodwill impairment, and a 3% full-year revenue decline. The company also disclosed an Audit Committee review into past biosimilar purchase timings and provided flat guidance for 2026.
Key Events
-
Q4 Net Loss Driven by Goodwill Impairment
The company reported a net loss of $205 million, or $0.79 per diluted share, for Q4 2025, primarily due to a $301 million non-cash goodwill impairment related to underperformance of several U.S. products. Non-GAAP Adjusted net income was $165 million, or $0.63 per diluted share.
-
Full Year 2025 Financial Performance
Full year 2025 revenue was $6.2 billion, a 3% decrease on both an as-reported and constant currency basis compared to 2024. Diluted EPS was $0.72, and non-GAAP Adjusted diluted EPS was $3.66. Adjusted EBITDA for the full year was $1.91 billion.
-
Audit Committee Initiates Review
Information was brought to the Audit Committee's attention on February 11, 2026, regarding the timing of biosimilar purchases from a supplier in prior years. A review will ensue, though the company has not determined any inappropriate conduct and anticipates timely filing of its Form 10-K.
-
Full Year 2026 Guidance
Organon expects full year 2026 revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion, both measures in-line with 2025 performance, indicating a flat outlook.
Analysis
Organon & Co. reported a net loss for the fourth quarter of 2025, primarily due to a substantial $301 million non-cash goodwill impairment related to underperforming U.S. products. This significant write-down, coupled with a 5% decline in Q4 revenue (8% ex-FX), indicates ongoing challenges in key segments. Furthermore, the company disclosed that its Audit Committee has initiated a review regarding the timing of biosimilar purchases from a supplier in prior years, introducing a new layer of uncertainty and potential risk, even though no inappropriate conduct has been determined yet. While the company projects flat revenue and Adjusted EBITDA for 2026, the combination of declining performance, a major impairment, and a pending audit review suggests a challenging outlook and warrants close investor attention.
At the time of this filing, OGN was trading at $7.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $6.18 to $17.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.